On December 10, 2020 Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, reported results from a prospective study showing Target Selector was highly accurate in monitoring HER2 alterations in patients with metastatic breast cancer (Press release, Biocept, DEC 10, 2020, View Source [SID1234572637]). The results were featured yesterday in a poster presentation by Vered Stearns, M.D., professor of oncology, breast cancer research chair in oncology, and director of the Women’s Malignancies Disease Group at Johns Hopkins University School of Medicine/Johns Hopkins Sidney Kimmel Cancer Center, at the virtual 2020 San Antonio Breast Cancer Symposium (SABC). The poster can be found under the "breast cancer" tab here.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Approximately 20% of newly diagnosed breast cancer is HER2 positive, but during treatment and as the disease progresses, HER2 receptor conversion may occur," said Dr. Stearns. "Once breast cancer metastasizes, it may be difficult to access multiple sites or perform serial tissue biopsies to monitor for conversion. In this study, liquid biopsy testing proved to be a highly sensitive and specific mechanism for monitoring HER2 receptor changes over time."
"Target Selector has been shown to be a highly sensitive blood-based testing method for identifying changes in HER2 status, and is less invasive, more time efficient and more cost effective compared to tissue biopsy," said Michael Nall, President and CEO. "Target Selector provides critical information to identify patients who may benefit from the addition of anti-HER2 therapy and those on anti-HER2 therapy for whom additional therapeutic options may warrant consideration."
About SABCS
Since 1977 the San Antonio Breast Cancer Symposium (SABCS) has been the leading scientific conference for basic scientists, physician-scientists, clinical investigators and breast care providers, and advocates seeking an exchange of new information in experimental biology, etiology, prevention, diagnosis and therapy of premalignant breast disease and breast cancer. Founded, owned and operated by UT Health San Antonio, the symposium has grown to a five-day event attended by an international audience of academic investigators and private physicians from over 80 countries to attain information through abstract presentations, panel discussions, research findings and state-of-the-art educational sessions. UT Health San Antonio, the American Association for Cancer Research (AACR) (Free AACR Whitepaper) and Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine support SABCS, which provides education and accessibility to the latest information regarding the prevention, diagnosis and treatment of premalignant breast cancer and breast disease. For more information about the symposium, please visit www.sabcs.org.